Compass Pathways

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

financial psychedelics (Zita and canadastock on Shutterstock)

Analyst Color

Cannabis

News

Health Care

Initiation

Analyst Ratings

Movers

Trading Ideas

General

CMPS

Compass Pathways gains Stifel&#39;s Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.

Psychedelics-Focused Compass Pathways Has Established Itself As &#39;Credible CNS Biotechnology Company,&#39; Analyst Says

Analysts

Markets

Hannon Armstrong Sustainable Infrastructure Capital

HASI

PLBC

This Plumas Bancorp Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday

2-11

Psychedelics

COMPASS Pathways faces $43M market cap loss, raising concerns among institutional investors holding 30% ownership.

COMPASS Pathways: Institutional Pressure Amid $43M Market Cap Decline, What&#39;s Next For This Psychedelics Co?

COMPASS Pathways Plc - American Depository Shares

Compass Pathways PLC

Press Releases

Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates

Compass Pathways to participate in Stifel 2024 Healthcare Conference

Compass Pathways to Participate in December Investor Conferences

Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI)

Compass Pathways Announces Pricing of Underwritten Offering

Compass Pathways Appoints Steve Levine, M.D., as Chief Patient Officer

Compass Pathways to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

Compass Pathways to Participate in TD Cowen 45th Annual Health Care Conference

Compass Pathways Announces Fourth Quarter and Full-Year 2024 Financial Results and Business Highlights

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics

Astria Therapeutics

aTyr Pharma

Aura Biosciences

Benitec Biopharma

Candel Therapeutics

Celcuity

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

Design Therapeutics

Emergent BioSolutions

Erasca

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Gossamer Bio

Heron Therapeutics

Immutep Limited - American Depositary Shares

Immutep

Mereo BioPharma Group plc - American Depositary Shares

Mereo BioPharma Group

Anbio Biotechnology - Class A Ordinary Shares

Anbio Biotechnology

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Oruka Therapeutics

Prime Medicine

Regenxbio

Tourmaline Bio

Taysha Gene Therapies, Inc. - Common Stock

Taysha Gene Therapies

Vanda Pharmaceuticals Inc. - Common Stock

Vanda Pharmaceuticals

Canaccord Genuity

Stifel

HC Wainwright & Co.

RBC Capital

Maxim Group

Comments

Compass Pathways

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga